Skip to main content

PerkinElmer to Perform Proteomics Analysis in Alzheimer s Research Partnership

NEW YORK, April 15 - PerkinElmer said today that it has entered a research collaboration with the Rush Alzheimer's Disease Center and the Buck Institute for Age Research to identify protein and gene targets involved in the onset and progression of Alzheimer's disease.


The Rush Alzheimer's Disease Center will supply brain tissue samples from patients who agreed to detailed annual clinical evaluations and brain donation at the time of death. The Buck Institute will perform genomic analysis on the tissue and PerkinElmer will perform proteomic studies to identify differentially expressed proteins in Alzheimer's and normal human brain tissue.


PerkinElmer and the Buck Institute said they would release their findings in a paper to be submitted later this year.


The proteomic analysis will be performed in PerkinElmer's Boston facility, and will involve up to 30 scientists led by Mary Lopez, director of biochemistry at PerkinElmer Life and Analytical Sciences.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.